How Does Psilocybin Affect Daily Life Experience and Behavior? Protocol For a Multimethod Ambulatory Assessment Study Within a Clinical Trial of Psilocybin for Depression

Introduction: Although psilocybin has shown promise for treating depression, responses vary considerably, with some individuals experiencing limiting improvement and even adverse effects. Research has largely relied on assessments conducted at discrete time points, providing limited insight into how post-psilocybin change unfolds in everyday life. The Dial-In study aims to characterize daily-life processes associated with differential responses to psilocybin, including factors associated with improvement or worsening following challenging dosing experiences. Methods and Analysis: Dial-In is a prospective, observational, multi-method longitudinal study embedded within a clinical trial administering 25 mg of psilocybin to up to 141 adults with major depressive disorder. Ambulatory assessments combine ecological momentary assessment (EMA) and voice diaries for 14 days pre- and post- dosing, and passive audio sampling via the Electronically Activated Recorder (EAR) for three four-day periods to characterize everyday affect, behavior, reflections, and social interactions. Outcomes include depressive symptoms, psychological well-being, and psychedelic-related adverse effects assessed through eight weeks post-dose. Analyses will examine whether affective sudden gains and losses, social support, interpersonal conflict, conversational focus, reflection and rigidity predict differential outcomes. Additional analyses will test whether these factors moderate associations between challenging dosing experiences and clinical outcomes. Ethics and Dissemination: The project was approved by WCG Institutional Review Board, with Emory University relying on WCG as the reviewing board. All participants provide written informed consent. Findings will be disseminated through peer-reviewed publications and scientific presentations.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.10.26367628
Primary Topic
Psychedelics and Drug Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

How Does Psilocybin Affect Daily Life Experience and Behavior? Protocol For a Multimethod Ambulatory Assessment Study Within a Clinical Trial of Psilocybin for Depression

Charles L. Raison, Santiago Jose Arconada Alvarez, Andreea Sutu, Christina J. Sauder et al.
medRxiv
Psychedelics and Drug Studies
preprint

How Does Psilocybin Affect Daily Life Experience and Behavior? Protocol For a Multimethod Ambulatory Assessment Study Within a Clinical Trial of Psilocybin for Depression

Charles L. Raison, Santiago Jose Arconada Alvarez, Andreea Sutu, Christina J. Sauder, Zhuo Job Chen, Roman Palitsky, Deanna M. Kaplan, Nicole S. Pozzo, Zainab Salako
preprint en

Abstract

Introduction: Although psilocybin has shown promise for treating depression, responses vary considerably, with some individuals experiencing limiting improvement and even adverse effects. Research has largely relied on assessments conducted at discrete time points, providing limited insight into how post-psilocybin change unfolds in everyday life. The Dial-In study aims to characterize daily-life processes associated with differential responses to psilocybin, including factors associated with improvement or worsening following challenging dosing experiences. Methods and Analysis: Dial-In is a prospective, observational, multi-method longitudinal study embedded within a clinical trial administering 25 mg of psilocybin to up to 141 adults with major depressive disorder. Ambulatory assessments combine ecological momentary assessment (EMA) and voice diaries for 14 days pre- and post- dosing, and passive audio sampling via the Electronically Activated Recorder (EAR) for three four-day periods to characterize everyday affect, behavior, reflections, and social interactions. Outcomes include depressive symptoms, psychological well-being, and psychedelic-related adverse effects assessed through eight weeks post-dose. Analyses will examine whether affective sudden gains and losses, social support, interpersonal conflict, conversational focus, reflection and rigidity predict differential outcomes. Additional analyses will test whether these factors moderate associations between challenging dosing experiences and clinical outcomes. Ethics and Dissemination: The project was approved by WCG Institutional Review Board, with Emory University relying on WCG as the reviewing board. All participants provide written informed consent. Findings will be disseminated through peer-reviewed publications and scientific presentations.

medRxiv
University of North Carolina at Charlotte (US), University of Wisconsin–Madison (US), Emory University (US)
Good health and well-being
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon